Keytruda showed a significant survival benefit over Tecentriq and Opdivo in older adults with metastatic NSCLC, with a 33% ...
The identification of 20 causal plasma proteins for prostate cancer represents a critical step toward addressing the need for improved diagnostic specificity and reveals promising new targets for ...
Once E3 tags CYP17A1, the cell uses its proteasome to break down the enzyme entirely. One major advantage of PROTACs is that ...
Regulators approved the injection, which significantly cuts administration time versus the intravenous formulation, based on a Phase III comparison of the two.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback